natgillin/translations-raw huggingface dataset:
Blandt de 1.618 dasatinib-behandlede patienter med CML i kronisk fase blev der rapporteret om bivirkninger, der medførte seponering, hos 329 patienter (20,3%), og blandt de 1.094 dasatinib-behandlede patienter med sygdom i fremskreden fase, blev der rapporteret om bivirkninger, der medførte seponering, hos 191 patienter (17,5%).
Among the 1,618 dasatinib-treated patients with chronic phase CML, adverse reactions leading to discontinuation were reported in 329 (20.3%) patients, and among the 1,094 dasatinib-treated patients with advanced phase disease, adverse reactions leading to discontinuation were reported in 191 (17.5%) patients.
Blandt de 11 forsøgspersoner udviklede 2 den emtricitabin-relaterede resistenssubstitution M184V.
Among the 11 subjects, 2 developed the emtricitabine-associated resistance substitution M184V.
Blandt de 122 patienter med målbare lymfeknuder både ved baseline og efter baseline opnåede 67 patienter (54,9 %) en ≥ 50 % reduktion fra baseline i summen af produkterne for diametrene (SPD, sum of the products of the diameters) af indekslæsionerne.
Among the 122 subjects with measurable lymph nodes at both baseline and post-baseline, 67 subjects (54.9%) achieved a ≥ 50% decrease from baseline in the sum of the products of the diameters (SPD) of index lesions.
Blandt de 1226 randomiserede patienter fik henholdsvis 89,4 % og 90,2 % af de patienter, der behandledes med placebo/FOLFIRI og ZALTRAP/FOLFIRI-regimet, forudgående oxaliplatin-baseret kombinations- kemoterapi i det metastaserende/avancerede miljø.
Among the 1226 randomised patients, 89.4% and 90.2% of patients treated with the placebo/FOLFIRI and ZALTRAP/FOLFIRI regimens, respectively, received prior oxaliplatin-based combination chemotherapy in the metastatic/advanced setting.
Blandt de 15.447 børn i catch-up-vaccineret-kohorterne blev der ikke fundet kulturbekræftet IPD- tilfælde i Synflorix-grupperne, mens der blev observeret 5 tilfælde af IPD forårsaget af vaccineserotyper i kontrolgrupperne (serotype 4, 6B, 7F, 14 og 19F).
Among the 15,447 children in the catch-up vaccinated cohorts, there were no culture-confirmed IPD cases in the Synflorix groups while 5 vaccine serotype IPD cases were observed in the control groups (serotypes 4, 6B, 7F, 14 and 19F).
Blandt de 167 patienter med HCV-genotype 1- infektion var 126 behandlingsnaive og hos 41 var tidligere behandling mislykket med PI-behandling (boceprevir eller telaprevir).
Among the 167 patients with HCV genotype 1 infection, 126 were treatment-naïve and 41 had failed prior therapy with a PI regimen (boceprevir or telaprevir).
Blandt de 17 MCI-patienter, som havde en positiv PET- scanning, blev 6 (35 %) diagnosticeret med klinisk sandsynlig AD 36 måneder senere, sammenlignet med 3 (10 %) af de 30, som havde en negativ scanning.
Of the 17 MCI patients who had a positive PET scan, 6 (35%) were diagnosed with clinical probable AD 36 months later compared to 3 (10%) of 30 who had a negative scan.
Blandt de 2.182 patienter med resistens eller intolerans over for tidligere imatinib-behandling, som fik SPRYCEL i kliniske studier, blev QTc-forlængelse indberettet som bivirkning hos 15 (1%) patienter.
2,182 patients with resistance or intolerance to prior imatinib therapy who received SPRYCEL in clinical studies, 15 (1%) had QTc prolongation reported as an adverse reaction.
Blandt de 4 patienter var sekvensdata fra parrede HBV-isolater fra baseline og under behandling tilgængelige for 2.
Among them, sequence data from paired baseline and on treatment HBV isolates were available for 2 of 4 patients.
Blandt de 47 patienter med en isoleret Del (5q) cytogenetisk anomali og behandlet med lenalidomid 10 mg opnåede 27 patienter (57,4 %) uafhængighed af transfusion af røde blodlegemer.
Amongst the 47 patients with an isolated Del (5q) cytogenetic abnormality and treated with lenalidomide 10 mg, 27 patients (57.4%) achieved red blood cell transfusion independence.
Blandt de 54% af patienterne (247/456), der fik samtidig kortikosteroidbehandling ved starten af PURSUIT-Maintenance, var anden del af patienterne, som opretholdt klinisk respons til og med uge 54, og som ikke fik samtidig kortikosteroidbehandling i uge 54, større i 50 mg-gruppen (38%, 30/78) og 100 mg-gruppen (30%, 25/82) end i placebogruppen (21%, 18/87).
Among the 54% of patients (247/456) who were receiving concomitant corticosteroids at the start of PURSUIT-Maintenance, the proportion of patients who maintained clinical response through week 54 and were not receiving concomitant corticosteroids at week 54 was greater in the 50 mg group (38%, 30/78) and 100 mg group (30%, 25/82) compared with the placebo group (21%, 18/87).
Blandt de 67 genotype 1a-smittede forsøgspersoner blev der observeret NS3- varianter hos 50, NS5A-varianter hos 46 og NS5B-varianter hos 37; hos 30 forsøgspersoner sås behandlingsrelaterede varianter i alle 3 lægemiddelmål.
In the 67 genotype 1a infected subjects, NS3 variants were observed in 50 subjects, NS5A variants were observed in 46 subjects, NS5B variants were observed in 37 subjects, and treatment- emergent variants were seen in all 3 drug targets in 30 subjects.
Blandt de 67 genotype 1a-smittede forsøgspersoner blev der observeret NS3-varianter hos 50, NS5A-varianter hos 46 og NS5B-varianter hos 37; hos 30 forsøgspersoner sås behandlingsrelaterede varianter i alle 3 lægemiddelmål.
In the 67 genotype 1a infected subjects, NS3 variants were observed in 50 subjects, NS5A variants were observed in 46 subjects, NS5B variants were observed in 37 subjects, and treatment- emergent variants were seen in all 3 drug targets in 30 subjects.
Blandt de 681 patienter med diarré afbrød 104 patienter (15 %) behandlingen, og 98 af disse patienter (94 %) genoptog senere bosutinib-behandlingen.
Among the 681 patients with diarrhoea, 104 patients (15%) were managed with treatment interruption and of these 98 (94%) were rechallenged with bosutinib.
Blandt de 7 genotype 1b- smittede forsøgspersoner blev der observeret behandlingsrelaterede NS3-varianter hos 4, NS5A- varianter hos 2 samt både NS3- og NS5A-varianter hos 1.
In the 7 genotype 1b infected subjects, treatment-emergent variants were observed in NS3 in 4 subjects, in NS5A in 2 subjects, and in both NS3 and NS5A in 1 subject.
Blandt de asiatiske patienter var forekomsten af febril neutropeni højere i Perjeta-gruppen (25,8 %) end i placebo-gruppen (11,3 %).
Among Asian patients, the incidence of febrile neutropenia was higher in the Perjeta-treated group (25.8%) compared with the placebo-treated group (11.3%).
Blandt de bivirkninger, der blev rapporteret med lige stor frekvens i disse kliniske forsøg hos patienter behandlet med filgrastim/kemoterapi og placebo/kemoterapi, var kvalme og opkastning, alopeci, diarré, træthed, anoreksi (nedsat appetit), mucositis, hovedpine, hoste, udslæt, brystsmerter, asteni, faryngolaryngeal smerte (orofaryngeal smerte) og forstoppelse.
In those clinical trials, undesirable effects reported with equal frequency in patients treated with filgrastim/chemotherapy and placebo/chemotherapy included nausea and vomiting, alopecia, diarrhoea, fatigue, anorexia (decreased appetite), mucosal inflammation, headache, cough, rash, chest pain, asthenia, pharyngolaryngeal pain (oropharyngeal pain) and constipation.
Blandt de børn, der blev behandlet i 24 eller 48 uger, reduceredes percentilen for alderen henholdsvis 1,3 og 9,0 percentiler fra før behandling til afslutning af langtidsopfølgningen.
From pre treatment to end of long-term follow up among children treated for 24 or 48 weeks, height for age percentiles decreased 1.3 and 9.0 percentiles, respectively.
Blandt de børn, der blev testet positive for antistoffer mod golimumab, havde 39% (25/69) neutraliserende antistoffer.
Among the children who tested positive for antibodies to golimumab, 39% (25/69) had neutralising antibodies.
Blandt de dasatanib-behandlede patienter, som fik pleuraeffusion (n=73), fik 45 (62%) afbrudt behandlingen og 30 (41%) fik dosis reduceret.
Among dasatinib-treated patients with drug-related pleural effusion (n=73), 45 (62%) had dose interruptions and 30 (41%) had dose reductions.
Blandt de dasatinib-behandlede patienter med pleuraeffusion opnåede 96% cytogenetisk respons (cCCyR), 82% opnåede MMR, og 50% opnåede MR4.5 på trods af afbrydelser i behandlingen eller dosisjusteringer.
Among the dasatinib-treated patients with pleural effusion, 96% achieved a cCCyR, 82% achieved a MMR, and 50% achieved a MR4.5 despite dose interruptions or dose adjustment.
Blandt de HBeAg-positive forsøgspersoner, der var randomiseret til tenofovirdisoproxilfumarat, oplevede 16 ud af 65 forsøgspersoner (25%) tab af HBeAg, og 8 ud af 65 forsøgspersoner (12%) oplevede anti-HBe-serokonversion til og med uge 240.
Among the HBeAg positive subjects randomised to tenofovir disoproxil fumarate, 16 of 65 subjects (25%) experienced HBeAg loss, and 8 of 65 subjects (12%) experienced anti-HBe seroconversion through week 240.
Blandt de hyppigst forekommende bivirkninger (korrigeret for placebo) optrådte følgende hyppigere ved behandling med Ranexa hos ældre ( 75 år) end hos yngre patienter (< 75 år): forstoppelse (8 % mod 5 %), kvalme (6 % mod 3 %), hypotension (5 % mod 1 %) og opkastning (4 % mod 1 %).
Of the most commonly reported, the following events occurred more often with Ranexa (placebo-corrected frequencies) in elderly ( 75 years of age) than younger patients (< 75 years of age): constipation (8% versus 5%), nausea (6% versus 3%), hypotension (5% versus 1%), and vomiting (4% versus 1%).
Blandt de hyppigste bivirkninger (hos mindst 2 % af patienter) i kliniske studier med levertransplanterede patienter, der fik Envarsus, var tremor, hovedpine, træthed, hyperkaliæmi, hypertension, nyresvigt, forhøjet blodkreatinin, svimmelhed, hepatitis C, muskelkramper, tineainfektion, leukopeni, sinusitis og URTI, som alle vides at forekomme hos den pågældende patientpopulation i immunsuppressiv behandling.
Among the most frequent adverse reactions (at least in 2% of patients) in clinical studies in liver transplant patients receiving Envarsus were tremor, headache, fatigue, hyperkalaemia, hypertension, renal failure, blood creatinine increased, dizziness, hepatitis C, muscle spasms, tinea infection, leukopenia, sinusitis , and URTI, all of which are known to occur in the respective patient population under immunosuppressive treatment.
Blandt de i alt 465 personer, som modtog ocriplasmin i de pivotale fase 3-studier, indberettede 19 (4,1 %) mindst 1 episode med bivirkningen "makulært ødem".
For the 465 ocriplasmin recipients in total in the pivotal phase 3 studies, 19 (4.1%) reported at least 1 episode of PT ‘macular oedema’.
Blandt de patienter, der blev behandlet med nivolumab i kombination med ipilimumab i CA209067, fik 151/313 (48%) de første grad 3 eller 4 bivirkninger i den indledende kombinationsfase.
Among the patients treated with nivolumab in combination with ipilimumab in CA209067, 151/313 (48%) had the first onset of Grade 3 or 4 adverse reactions during the initial combination phase.
Blandt de patienter, der blev i studiet og fik behandling med Simponi, sås samme ACR-respons på 20-/50-70 fra uge 104 til og med uge 256.
Among patients remaining in the study and treated with Simponi, similar rates of ACR 20/50/70 response was observed from week 104 through week 256.
Blandt de patienter, der blev i studiet og fik behandling med Simponi, var DAS28-responset det samme fra uge 104 til og med uge 256.
Among patients remaining in the study and treated with Simponi, DAS28 and HAQ DI responses were similar from week 104 through week 256.
Blandt de patienter, der blev i studiet og fik behandling med Simponi, var de radiografiske virkninger de samme fra uge 104 til og med uge 256.
Among patients remaining in the study and treated with Simponi, similar rates of patients showed no progression from baseline from week 104 through week 256.
Blandt de patienter, der blev i studiet og fik behandling med Simponi, var forbedringen i den fysiske komponent SF-36 den samme fra uge 104 til og med uge 256.
Among patients remaining in the study and treated Simponi, improvement of the SF-36 physical component was similar from week 104 through week 256.
Blandt de patienter, der blev i studiet og fik behandling med Simponi, viste et lignende antal patienter ingen progression fra uge 104 til og med uge 256.
Among patients remaining in the study and treated with Simponi, similar rates of patients showed no progression from baseline from week 104 through week 256.
Blandt de patienter, der blev inkluderet i 12-måneders open-label perioden, havde 59% (125/213) af de patienter, som kontinuerligt fik abatacept plus methotrexat-behandling og 48% (92/192) af de patienter, som oprindeligt fik methotrexat og skiftede til kombination med abatacept, ingen progression.
Among the patients who entered the open-label 12 month period, 59% (125/213) of patients receiving continuous abatacept plus methotrexate treatment and 48% (92/192) of patients who initially received methotrexate and switched to combination with abatacept had no progression.
Blandt de patienter, der fik antikoagulantia, var hyppigheden af blødningshændelser omtrent den samme i OZURDEX-gruppen som i gruppen, der fik sham (29 % versus 32 %).
Among patients who used anti-coagulant therapy, the frequency of haemorrhagic adverse events was similar in the OZURDEX and sham groups (29% vs 32%).
Blandt de patienter, der fik behandling med Epclusa + RBV i 12 uger, havde 29 % (25/85) af patienterne virus med NS5A–RAV’er ved baseline: 29 % (19/66), 75 % (3/4), 15 % (2/13) og 50 % (1/2) for patienter med henholdsvis genotype 1-, 2-, 3- og 4-HCV.
Among the patients who received treatment with Epclusa + RBV for 12 weeks, 29% (25/85) of patients had baseline virus with NS5A RAVs: 29% (19/66), 75% (3/4), 15% (2/13), and 50% (1/2) for patients with genotype 1, 2, 3 and 4 HCV, respectively.
Blandt de patienter, der havde tumorer med adenokarcinom-histologi, havde 15,8 % sygdomsstadium < IIIB/IV, 15,2 % havde sygdomsstadium IIIB, og 69,0 % havde sygdomsstadium IV.
For patients with tumour of adenocarcinoma histology, 15.8 % had disease stage < IIIB/IV, 15.2 %, had disease stage IIIB and 69.0 % had disease stage IV.
Blandt de patienter, der indledningsvist blev randomiseret til behandling med apremilast 30 mg to gange dagligt, var ændringen fra baseline i HAQ-DI-score efter uge 52 -0,333 i gruppen med apremilast 30 mg i de samlede analyser af open label-faserne i studierne PALACE 1, PALACE 2 og PALACE 3.
Among patients who were initially randomized to apremilast 30 mg twice daily treatment, the change from baseline in the HAQ-DI score at week 52 was -0.333 in the apremilast 30 mg twice daily group in a pooled analysis of the open label phase of studies PALACE 1, PALACE 2 and PALACE 3.
Blandt de patienter, der udviklede resistens over for rilpivirin, havde 4/7 patienter med baseline viral belastning ≤ 100.000 kopier/ml og 28/30 patienter med baseline viral belastning > 100.000 kopier/ml krydsresistens over for andre NNRTI’er.
Among those patients who developed resistance to rilpivirine, 4/7 patients with baseline viral load ≤ 100,000 copies/mL and 28/30 patients with baseline viral load > 100,000 copies/mL had cross-resistance to other NNRTIs.
Blandt de patienter, som fik Tarceva, var den gennemsnitlige overlevelsestid 8,6 måneder for dem, hvis kræft var "EGFR IHC-positiv" (dvs. som havde EGFR'er på kræftcellernes overflade), sammenlignet med 5,0 måneder for dem, hvis kræft var "EGFR IHC-negativ".
Among the patients who took Tarceva, the average survival was 8.6 months in those whose tumours were ‘EGFR IHC-positive’ (had EGFRs on their surface), and 5.0 months in those whose tumours were EGFR IHC-negative.
Blandt de patienter, som ikke havde respons i uge 4, responderede 43 % af patienterne i Humira vedligeholdelsesbehandling ved uge 12 sammenlignet med 30 % af patienter i placebogruppen.
Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by Week 12 compared to 30% of placebo maintenance patients.
Blandt de patienter, som ikke havde respons i uge 4, responderede 43 % af patienterne i Humira- vedligeholdelsesbehandling ved uge 12 sammenlignet med 30 % af patienter i placebogruppen.
Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by Week 12 compared to 30% of placebo maintenance patients.
Blandt de patienter, som responderede ved uge 16 (n=144), blev de pædiatriske ACR 30/50/70/90- responser opretholdt i op til seks år i den åbne forlængelsesfase hos dem, der fik Humira gennem hele studiet.
Amongst those who responded at Week 16 (n=144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received Humira throughout the study.
Blandt de patienter, som responderede ved uge 16 (n=144), blev pædiatrisk ACR 30/50/70/90- responser opretholdt i op til seks år i den åbne forlængelsesfase hos dem, der fik Humira gennem hele studiet.
Amongst those who responded at Week 16 (n=144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received Humira throughout the study.
Blandt de patienter, som responderede ved uge 16 (n=144), blev pædiatrisk ACR 30/50/70/90-respons opretholdt i op til seks år i den åbne forlængelsesfase hos dem, der fik Humira gennem hele studiet.
Amongst those who responded at Week 16 (n=144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received Humira throughout the study.
Blandt de sidste finder tre undersøgelser kun sådan en øgning hos patienter, hos hvem plasma- mitotanniveauet er over 14 mg/l.
Among the latter, three studies find such an increase only in patients in whom mitotane plasma is above 14 mg/l.
Blandt de testede kovariater, der var relaterede til alder og legemsstørrelse, var alder en signifikant kovariat for den tilsyneladende clearance af sunitinib (jo yngre den pædiatriske patient var, jo lavere tilsyneladende clearance).
Among age and body-size related covariates tested, age was a significant covariate on apparent clearance of sunitinib (the younger the age of the paediatric patient, the lower the apparent clearance).
Blandt deltagere i studier til behandling af osteoporose forekom behandlings- ophør som følge af enhver bivirkning hos 12,8 % af 2.557 Evista-behandlede patienter og hos 11,1 % af 2.576 placebo-behandlede patienter.
In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8 % of 2,557 Evista treated patients and 11.1 % of 2,576 placebo treated patients.
Blandt deltagere i studier til behandling af osteoporose forekom behandlings- ophør som følge af enhver bivirkning hos 12,8 % af 2.557 Optruma-behandlede patienter og hos 11,1 % af 2.576 placebo-behandlede patienter.
In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8 % of 2,557 Optruma treated patients and 11.1 % of 2,576 placebo treated patients.
Blandt dem der tog Truvada, blev 0,8 % (13 ud af 1 576) testet positive for hiv-1-infektion i løbet af 1 år, sammenlignet med 3,3 % (52 ud af 1 578) af dem, der tog placebo.
Of the individuals taking Truvada, 0.8% (13 out of 1,576) tested positive for HIV-1 infection over 1 year compared with 3.3% (52 out of 1,578) of those taking placebo.
Blandt dem oplevede to patienter en klinisk betydningsfuld reduktion i estimeret GFR, som bedredes efter seponering af tenofovirdisoproxilfumarat.
Among them, two patients experienced a clinically meaningful decline in estimated GFR which improved after discontinuation of tenofovir disoproxil fumarate.
Blandt den samlede population på 2.712 patienter, der blev behandlet med SPRYCEL, oplevede 520 (19%) bivirkninger, der medførte seponering.
In the overall population of 2,712 SPRYCEL treated patients, 520 (19%) experienced adverse reactions leading to treatment discontinuation.
Blandt disse 1.053 kvinder blev sikkerheden af gentagne intermitterende behandlingsforløb (hver især begrænset til 3 måneder) evalueret hos 551 kvinder med uterusfibromer i to fase III-studier (inkl.
Among these 1,053 women, the safety of repeated intermittent treatment courses (each limited to
Blandt disse 10 hiv 1-isolater var de mutationer, der opstod, M184V/I (n = 9) og K65R/N (n = 2) i RT og T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) og N155H (n = 2) i integrase.
Among these 10 HIV-1 isolates, the mutations that emerged were M184V/I (n = 9) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase.
Blandt disse 56 patienter viste 25 (44,6 %) også tilstedeværelse af neutraliserende antistoffer.
Among those 56 patients, 25 (44.6%) also showed the presence of neutralizing antibodies.
Blandt disse blev 1.585 kvinder behandlet med konjugeret østrogen 0,45 mg/bazedoxifen 20 mg og 1.241 fik placebo.
Among these, 1,585 women were treated with CE 0.45 mg/bazedoxifene 20 mg and 1,241 received placebo.
Blandt disse børn blev de vaccinerelaterede bivirkninger, der er opsummeret under punkt b., observeret hos personer efter vaccination med M-M- RVAXPRO (bortset fra enkeltstående indberetninger med en hyppighed <0,2 %).
Among these children, the vaccine-related adverse reactions, summarised in section b, were observed in individuals following vaccination with M-M-RVAXPRO (excluding isolated reports with frequency <0.2%).
Blandt disse børn blev der observeret de vaccinerelaterede bivirkninger, der er opsummeret i pkt. b, hos personer efter vaccination med M-M- RVAXPRO (bortset fra enkeltstående indberetninger med en hyppighed < 0,2 %).
Among these children, the vaccine-related adverse reactions, summarised in section b, were observed in individuals following vaccination with M-M-RVAXPRO (excluding isolated reports with frequency <0.2%).
Blandt disse fejlslagne behandlinger var 6 Cubicin- behandlede patienter og 1 vancomycin-behandlet patient, som udviklede tiltagende MICer på eller efter behandling (se ”Resistensmekanisme” ovenfor).
Among these failures six patients treated with Cubicin and one patient treated with vancomycin were infected with Staphylococcus aureus that developed increasing MICs of daptomycin on or following therapy (see “Mechanisms of resistance” above).
Blandt disse havde 86, 72 og 41 patienter ACR response på henholdvis 20/50/70 ved 60 måneder
Among those, 86, 72, and 41 patients had ACR 20/50/70 response, respectively at month 60.
Blandt disse patienter blev der opnået klinisk remission hos 23 % af patienterne i uge 28 og hos 32 % af patienter i uge 52.
In these patients, clinical remission was achieved in 23% of patients at Week 28 and 32% of patients at Week 52.
Blandt disse patienter havde 36 CML i kronisk fase, og 16 havde CML i accelereret fase eller blastfase.
Among these patients, 36 had chronic phase CML and 16 patients had either accelerated or blast phase CML.
Blandt disse patienter med normal TSH ved baseline blev der observeret et forhøjet niveau af TSH over 0,5 mE/l efter baseline hos 57 % i lenvatinib-gruppen sammenlignet med 14 % i placebogruppen.
0.5 mU/L. In those patients with a normal TSH at baseline, elevation of TSH level above 0.5 mU/L was observed post baseline in 57% of lenvatinib-treated patients as compared with 14% of placebo-treated patients.
Blandt disse patienter oplevede 125 patienterne (56 %) maksimalt grad 1- eller 2-toksicitet, 76 patienterne (34 %) grad 3 og 23 patienterne (10 %) grad 4.
In these patients, the maximum toxicity of Grade 1 or 2 was experienced in 125 (56%) patients, Grade 3 in 76 patients (34%), and Grade 4 in 23 (10%) patients.
Blandt disse patienter opnåede 28 %, der fik vedolizumab hver 8. uge, 27 %, der fik vedolizumab hver 4. uge, og 13 %, der fik placebo, klinisk remission i uge 52.
Among these patients, 28% receiving vedolizumab every eight weeks, 27% receiving vedolizumab every four weeks, and 13% receiving placebo achieved clinical remission at Week 52.